Evaluating antibody–drug conjugates (ADCs) early in development requires more than traditional endpoint viability assays, which can miss critical information about killing kinetics and target specificity.
In this application note, we demonstrate how the Maestro Z measures ADC-mediated cancer cell killing continuously, in real time, and without labels using impedance technology.
Inside the Application Note:
>> Real-time monitoring of HER2-targeted ADC killing
>> Clear differentiation between HER2-high and HER2-low cell responses
>> Dose-response analysis and EC50 determination
>> Head-to-head comparison of clinically relevant ADCs
See how impedance-based assays reveal killing dynamics not captured by endpoint assays—helping accelerate ADC candidate evaluation and reduce development risk.
